Kite Pharma, Inc. 4
4 · Kite Pharma, Inc. · Filed Jul 6, 2017
Insider Transaction Report
Form 4
Wiezorek Jeffrey
VP Clinical Development
Transactions
- Sale
Common Stock
2017-07-03$104.26/sh−8,799$917,384→ 22,272 total - Exercise/Conversion
Common Stock
2017-07-03$6.89/sh+10,000$68,900→ 31,071 total - Sale
Common Stock
2017-07-03$104.76/sh−1,201$125,817→ 21,071 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2017-07-03−10,000→ 58,000 totalExercise: $6.89Exp: 2024-06-05→ Common Stock (10,000 underlying)
Footnotes (4)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 30, 2017.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.65 to $104.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.65 to $104.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F4]25% of the 175,000 shares originally subject to the stock option vested and became exercisable on May 5, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.